Celldex Therapeutics, Inc. (CLDX) Net margin 2016–2025
Celldex Therapeutics, Inc. (CLDX) net profit margin by fiscal year — reported net income divided by reported revenue.
-16748.0%FY2025 · since FY2016: -1894.0% → -16748.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -16748.0% | -14499.3 pp |
| FY2024 | -2248.8% | -194.0 pp |
| FY2023 | -2054.8% | +2710.8 pp |
| FY2022 | -4765.6% | -3249.6 pp |
| FY2021 | -1516.0% | -710.2 pp |
| FY2020 | -805.9% | +618.1 pp |
| FY2019 | -1424.0% | +161.1 pp |
| FY2018 | -1585.1% | -855.0 pp |
| FY2017 | -730.1% | +1164.0 pp |
| FY2016 | -1894.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CLDX financial trends
CLDX RevenueCLDX Net incomeCLDX Gross profitCLDX Gross marginCLDX Operating incomeCLDX Operating marginCLDX Operating cash flowCLDX Free cash flowCLDX Capital expendituresCLDX Return on equityCLDX Stock buybacksCLDX Dividends paidCLDX Total assetsCLDX Total liabilitiesCLDX Shareholders’ equityCLDX overview →